NCT00088582View on ClinicalTrials.gov

Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

March 31, 2004

Primary Completion Date

October 31, 2005

Conditions
Acromegaly
Interventions
DRUG

Pasireotide (SOM230), Octreotide (Sandostatin)

Trial Locations (5)

10010

New York University/VA Medical Center, New York

22908

University of Virginia Health System, Charlottesville

48108

University of Michigan Medical Center, Ann Arbor

90048

Cedars Sinai Medical Center, Los Angeles

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY